MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Kodu・Aktsiate loetelu・Xencor Inc

Xencor Inc

Avatud

SektorTervishoid

11.83 0.85

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.65

Max

11.96

Põhinäitajad
By Trading Economics
Sissetulek	18M -31M
Müük	11M 44M
Kasumimarginaal	-70.687
Töötajad	250
EBITDA	17M -20M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+91.89% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. nov 2025

Turustatistika
By TradingEconomics
Turukapital	259M 825M
Eelmine avamishind	10.98
Eelmine sulgemishind	11.83

Uudiste sentiment

By Acuity

50%

149 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

7.87 / 10.84 Toetus ja vastupanu

Xencor Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. okt 2025, 23:30 UTC

Kuumad aktsiad

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2. okt 2025, 21:21 UTC

Tulu

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3. okt 2025, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2. okt 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2. okt 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2. okt 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2. okt 2025, 22:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Scales's JV Buyout Lauded by Bull -- Market Talk

2. okt 2025, 22:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Forex and Fixed Income Roundup: Market Talk

2. okt 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2. okt 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. okt 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2. okt 2025, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

2. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. okt 2025, 20:49 UTC

Omandamised, ülevõtmised, äriostud

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2. okt 2025, 20:00 UTC

Omandamised, ülevõtmised, äriostud

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2. okt 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2. okt 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2. okt 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2. okt 2025, 18:45 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2. okt 2025, 18:45 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2. okt 2025, 18:43 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Võrdlus sarnastega

Hinnamuutus

Xencor Inc Prognoos

Hinnasiht

By TipRanks

91.89% tõus

12 kuu keskmine prognoos

Keskmine 22.7 USD 91.89%

Kõrge 40 USD

Madal 6 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Xencor Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Xencor Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

7.87 / 10.84Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

149 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.